Skip to content
Pfizer in advanced talks to buy Global Blood Therapeutics for about $5 billion

Pfizer is in advanced talks to buy Global Blood Therapeutics the maker of a recently approved sickle cell drug, worth around $5 billion, in the pharma giant’s latest move to bolster its portfolio and pipeline.

Pfizer is aiming to strike a deal for GBT in the coming days, according to people familiar with the matter. The situation is still fluid and other suitors are still in the mix, some people said. GBT announces its second quarter results on Monday.

wsj

Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.